2,270 reports of this reaction
3.5% of all IPILIMUMAB reports
#5 most reported adverse reaction
COLITIS is the #5 most commonly reported adverse reaction for IPILIMUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 2,270 FDA adverse event reports linking IPILIMUMAB to COLITIS. This represents approximately 3.5% of all 65,125 adverse event reports for this drug.
Patients taking IPILIMUMAB who experience colitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLITIS is moderately reported among IPILIMUMAB users, representing a notable but not dominant share of adverse events.
In addition to colitis, the following adverse reactions have been reported for IPILIMUMAB:
The following drugs have also been linked to colitis in FDA adverse event reports:
COLITIS has been reported as an adverse event in 2,270 FDA reports for IPILIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLITIS accounts for approximately 3.5% of all adverse event reports for IPILIMUMAB, making it a notable side effect.
If you experience colitis while taking IPILIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.